Precision BioSciences (DTIL) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 12.8% versus a loss of 26.4%. Over five years, IPHA leads with a -74.8% price change compared with -97.8% for DTIL. Precision BioSciences is the larger company by market cap ($186.6 million vs $172.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | IPHA |
|---|---|---|
| Share price | $6.76 | $1.54 |
| Market cap | $186.59M | $172.02M |
| 1-day change | +5.13% | +4.05% |
| YTD return | +54.57% | -15.43% |
| 1-year return | +12.81% | -26.37% |
| 5-year return | -97.81% | -74.79% |
| EPS (TTM) | $-1.35 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $2.71 |
| 52-week low | $3.53 | $1.17 |
| Distance from 52-week high | -29.73% | -43.17% |
| Analyst consensus | none | none |
| Avg. price target upside | +334.91% | +333.12% |
| Average volume | 287.13K | 156.96K |
| Shares outstanding | 27.60M | 111.70M |
| Employees | 67 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed IPHA by 39.2 percentage points over the past year.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
DTIL vs IPHA FAQ
Which is bigger, Precision BioSciences or Innate Pharma S.A.?
Precision BioSciences (DTIL) is larger, with a market capitalization of $186.59M compared with $172.02M for Innate Pharma S.A. (IPHA).
Which stock has performed better over the past year, DTIL or IPHA?
DTIL returned +12.81% over the past 12 months, compared with -26.37% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and Innate Pharma S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.